Pharmaceutical - Diabetes, Research

Filter

Current filters:

DiabetesResearch

Popular Filters

1 to 25 of 137 results

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

EASD 2014: AstraZeneca highlights range of choice in its diabetes portfolio

29-09-2014

Diabetes is a firm priority of UK-based pharma major AstraZeneca and is in no danger of being side-lined,…

AstraZenecaBydureonDiabetesForxigaInterviewsOnglyzaPharmaceuticalResearchUK

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

AstraZeneca’s Byetta meets primary endpoint in diabetes trial and reduces weight

24-09-2014

UK-based pharma major AstraZeneca has announced new research showing that Byetta (exenatide) added to…

AstraZenecaByettaDiabetesGlucagonPharmaceuticalResearchUK

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

EASD 2014: Novo Nordisk updates on Ryzodeg, Tresiba and Xultophy

19-09-2014

The global burden of diabetes is growing fast with an astonishing 10% of global healthcare expense spent…

DenmarkDiabetesEuropeMexicoNovo NordiskPharmaceuticalResearchRyzodegTresibaXultophy

First Ph III data in Japanese patients for Merck’s omarigliptin for type 2 diabetes

18-09-2014

US pharma giant Merck & Co has announced the presentation of the first data from the Phase III clinical…

DiabetesJapanMerck & CoomarigliptinPharmaceuticalRegulationResearch

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

Novo Nordisk’s Tresiba shows long-term efficacy and safety in diabetic children and adolescents

16-09-2014

Danish diabetes care giant Novo Nordisk announced positive new data from the BEGIN YOUNG 1 trial today,…

DiabetesNovo NordiskPharmaceuticalResearchTresiba

Empagliflozin/linagliptin combo shows sustained reduction in blood glucose in Ph III

16-09-2014

Family-owned German pharma major Boehringer Ingelheim and US partner Eli Lilly have presented results…

Boehringer IngelheimDiabetesEli LillyempagliflozinlinagliptinPharmaceuticalResearch

Lilly's peglispro shows HbA1c superiority against Lantus in Ph III trials

Lilly's peglispro shows HbA1c superiority against Lantus in Ph III trials

04-09-2014

US pharma major Eli Lilly has released additional clinical data showing superiority for its diabetes…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

Insulin offers new hope for the treatment of acute pancreatitis

22-08-2014

Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting…

DiabetesInflammatory diseasesPancreas disordersPharmaceuticalResearchUK

Positive new Ph III data with Novo Nordisk’s Xultophy

Positive new Ph III data with Novo Nordisk’s Xultophy

11-08-2014

Positive new pivotal Phase III data about Xultophy (insulin degludec/liraglutide), formerly known as…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchXultophy

A$35 million to advance Australian type 1 juvenile diabetes research

A$35 million to advance Australian type 1 juvenile diabetes research

10-07-2014

Australia’s Minister for Education, Christopher Pyne, and Minister for Health, Peter Dutton, have today…

AustraliaDiabetesFinancialPharmaceuticalResearch

ImmuPharma extends research capabilities via French connection

27-06-2014

UK-based drug discovery firm ImmuPharma has extended its research capabilities by setting up its own…

DiabetesImmuPharmaPharmaceuticalResearchUrelix

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

Sanofi facing triple threat from Eli Lilly for diabetes treatment market space

26-06-2014

The imminent patent expiration of French pharma major Sanofi’s Lantus (insulin glargine) has opened…

BiosimilarsDiabetesdulaglutideEli LillyIDegLiraLantusLixiLanMarkets & MarketingNovo NordiskPharmaceuticalResearchSanofiToujeo

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

23-06-2014

New data for Danish diabetes care giant Novo Nordisk’s liraglutide 3mg from the Phase IIIa SCALET Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

15-06-2014

A new Phase IIIa study shows that IDegLira, the once-daily single injection combination of Danish diabetes…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchVictoza

ADA 2014: Positive Ph III Results for Sanofi’s Toujeo

ADA 2014: Positive Ph III Results for Sanofi’s Toujeo

15-06-2014

French pharma major Sanofi has released data from a pooled analysis, investigational therapy Toujeo (insulin…

DiabetesPharmaceuticalResearchSanofiToujeo

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

15-06-2014

Patients enrolled in of four randomized Phase III studies who remained on Tanzeum/Eperzan (albiglutide),…

Anti-diabetic drugsDiabetesGlaxoSmithKlineGSKMajorPharmaceuticalResearchStudy protocolStudy protocolTanzeumUK

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

AstraZeneca’s Bydureon controls diabetes better than insulin glargine

30-05-2014

Anglo-Swedish pharma major AstraZeneca has announced that Bydureon (exenatide once-weekly injection)…

Anti-diabetic drugsAstraZenecaBydureonDiabetesGlucagonPharmaceuticalResearchUK

Significantly greater weight loss versus placebo seen in Ph IIIa study of liraglutide 3mg

16-05-2014

Significant weight loss was demonstrated for Danish insulin giant Novo Nordisk’s diabetes drug liraglutide…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

Lilly's basal insulin peglispro beats insulin glargine in HbA1c reduction for type 2 diabetes

13-05-2014

US pharma major Eli Lilly has released positive top-line results of three completed Phase III clinical…

DiabetesEli LillyLantuspeglisproPharmaceuticalResearchSanofi

GW Pharmaceuticals updates on cannabinoid pipeline

GW Pharmaceuticals updates on cannabinoid pipeline

17-03-2014

UK biopharma company GW Pharmaceuticals this morning provided an update on the company’s cannabinoid…

DiabetesepidiolexGW PharmaceuticalsGWP42004GWP42006NeurologicalPharmaceuticalResearchSativex

Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan

09-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

05-03-2014

Danish insulin giant Novo Nordisk has presented positive data at the Diabetes UK conference from its…

DenmarkDiabetesIDegLiraNovo NordiskPharmaceuticalResearchUK

Australian patients benefit from PBS changes; cancer research

27-02-2014

New medicines for glaucoma, diabetes and advanced soft tissue sarcoma have been approved for listing…

Asia-PacificAustraliaDiabetesFinancialHealthcareKombiglyzeOncologyPharmaceuticalResearchTrajentaVotrient

1 to 25 of 137 results

Back to top